11/20 #TumorBoardTuesday 💡Mini tweetorial 6 Evidence supporting metastasis-directed therapy (MDT) for oligomets Pooling 📚STOMP + 📚ORIOLE Pts: PCa recurrence low-volume met (no high-risk mut) Obs vs MDT (no systemic Tx) Median PFS: 7.0 months Obs vs 13.4 months w/ MDT

12/20 #TumorBoardTuesday 💡Mini tweetorial 6.5 🔬Ongoing trials of MDT in de novo oligomets mCSPC (NCT03298087, NCT03784755, NCT03763253, NCT05223803) 📚 NCCN recs ⚡SBRT to oligometas from PCa when (1) goal is ablation (2) limited progression or (3) symptomatic lesion

13/20 #TumorBoardTuesday 📋Back to our case 65M with de novo low-volume mCSPC Prostate RT 5500 cGy ⚡ in 20 fractions SBRT 2000 cGy ⚡X5 fractions to T7 and L3 mets SBRT 4000 cGy ⚡ X5 fractions to L iliac met

14/20 #TumorBoardTuesday 📋Back to our case 65M with de novo low-volume mCSPC Within 3 months, PSA <0.02 Interval NM bone scan/CT scan at 6 months shows stable sclerotic bone mets with resolution of activity in corresponding lesions🩻

15/20 #TumorBoardTuesday 💡Mini tweetorial 7 Sig of rapid, deep, and durable PSA declines with apa + ADT Post-hoc analysis of 📚TITAN, median 44.0 mo Pts: mCSPC getting ADT + apa Achieved: >90% PSA decline or PSA <0.2 ng/ml at 3 months Median OS: 37.7 months “Not achieved” vs

16/20 #TumorBoardTuesday Unmet needs in mCSPC ADT intensification underutilized in real-world studies Pts: mCSPC (2013-2018)

17/20 #TumorBoardTuesday Lack of an established biomarker to guide 1L therapies in mCSPC 🔬Studies ongoing, e.g. SPOP mutations 🧬may be predictive for ARPI + ADT

18/20 #TumorBoardTuesday Summary 1L mCSPC therapies stratified by volume High volume: Triplet therapies or ADT + ARPI (based on pt factors) Low volume: ADT + ARPI (based on pt factors)

19/20 #TumorBoardTuesday Summary For low-volume mCSPC (mHSPC) Benefit for local therapy to primary tumor Benefit of metastasis-directed therapy (MDT)

Cancer research fuels life-saving work, writes Cedars-Sinai's Ze'ev Ronai. cancerletter.com/guest-editoria…

A meeting for my #SoCal colleagues. No lengthy travel required. Join us in #NewportBeach to discuss the current status of clinical trials in our area for #kidneycancer, #bladdercancer and #prostatecancer. Keynote from Andrea Necchi, our “external reviewer”, who will be offering

🚨 We need your help! 🏛 This Tuesday, March 11, 2025, Congress will begin votes on a continuing resolution that includes a devastating 57% cut to the Department of Defense’s Congressionally Directed Medical Research Program. The Prostate Cancer Research Program has been

🚨As early as tomorrow, congress may act on a proposal to cut DOD research funding. This will devastate biomedical research in the US. 👇Please act now by contacting your representatives with the link below Prostate Cancer Foundation PCF Science Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine UCLA Urology